Year Ended December 31,
(MILLIONS, EXCEPT PER COMMON SHARE DATA) 2021 2020 2019
Revenues $ 81,288 $ 41,651 $ 40,905
Costs and expenses:
Cost of sales(a) 30,821 8,484 8,054
Selling, informational and administrative expenses(a) 12,703 11,597 12,726
Research and development expenses(a) 13,829 9,393 8,385
Amortization of intangible assets 3,700 3,348 4,429
Restructuring charges and certain acquisition-related costs 802 579 601
(Gain) on completion of Consumer Healthcare JV transaction — (6) (8,107)
Other (income)/deductions––net (4,878) 1,219 3,497
Income from continuing operations before provision/(benefit) for taxes on income 24,311 7,036 11,321
Provision/(benefit) for taxes on income 1,852 370 583
Income from continuing operations 22,459 6,666 10,738
Discontinued operations––net of tax (434) 2,529 5,318
Net income before allocation to noncontrolling interests 22,025 9,195 16,056
Less: Net income attributable to noncontrolling interests 45 36 29
Net income attributable to Pfizer Inc. common shareholders $ 21,979 $ 9,159 $ 16,026